{"id":80587,"date":"2023-07-11T11:46:55","date_gmt":"2023-07-11T11:46:55","guid":{"rendered":"https:\/\/dailytalks.org\/?p=80587"},"modified":"2023-07-11T11:46:55","modified_gmt":"2023-07-11T11:46:55","slug":"bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=80587","title":{"rendered":"Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy"},"content":{"rendered":"<p>Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients \u00a0\/ Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause\u00a0Berlin, October 17, 2022 \u2013 Bayer, a global leader in women\u2019s healthcare&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy<\/p>\n","protected":false},"author":1,"featured_media":80588,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43],"tags":[],"class_list":["post-80587","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/07\/80587-bayer-expands-development-program-for-elinzanetant-with-phase-iii-study-in-breast-cancer-patients-with-vasomotor-symptoms-caused-by-endocrine-therapy-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=43\" rel=\"category\">Health<\/a>","tag_info":"Health","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/80587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=80587"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/80587\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/80588"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=80587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=80587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=80587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}